# GPT-5.6 Sol / mol-r01

Original final answer, shared by both scoring rounds.

# Recommended decisive next step

Ask whether the cleavage-matched amino-terminal GSDMD fragment is, by itself, sufficient to bind and permeabilize a protein-free lipid bilayer at a membrane exposure comparable to that reached in the tested cells—and whether selectively removing that biochemical activity also removes cellular lysis despite normal GSDMD production, cleavage, and membrane recruitment.

The most informative study therefore has two linked parts:

1. **Minimal reconstitution:** purified amino-terminal GSDMD plus chemically defined, protein-free membranes.
2. **Cellular causality:** separation-of-function GSDMD variants whose behavior in the reconstitution predicts their ability to restore lysis in GSDMD-deficient cells.

A negative reconstitution alone would not establish an indirect mechanism, because the recombinant fragment or membrane composition could be inappropriate. If direct activity is not detected after those possibilities are addressed, the study should branch into cellular-fraction add-back, purification, and genetic validation of a downstream effector.

No proposed result below should be read as observed.

---

## 1. Unresolved biological question

**Does liberated amino-terminal GSDMD directly compromise membrane integrity, or does it activate another cellular protein or pathway that is the immediate membrane-disrupting effector?**

For this study, “direct membrane action” means that amino-terminal GSDMD binds and permeabilizes a defined lipid bilayer without any other cellular protein, nucleotide-consuming system, or cell extract. Lipids may determine susceptibility, but no second cellular macromolecular effector is required.

### Competing mechanisms

#### Mechanism D: direct membrane action

Cleavage releases an autoinhibited membrane-active domain. The amino-terminal domain directly associates with the bilayer and causes permeability, whether by forming stable conductive lesions, transient defects, or broader membrane disruption.

**Predictions**

- Purified amino-terminal GSDMD should bind and permeabilize protein-free liposomes.
- The intact autoinhibited protein should be much less active under matched conditions.
- Permeability should depend on amino-terminal GSDMD concentration or membrane surface density and should have measurable kinetics.
- The same preparation should alter an independent membrane measurement, such as planar-bilayer conductance or single-vesicle permeability.
- Variants that specifically lose membrane binding or permeabilization should lose cellular lytic activity even if expression, cleavage, folding, and—in the strongest case—membrane localization remain intact.

#### Mechanism E: activation of another cellular effector

The liberated domain is a signaling or activating ligand for a cellular protein, protein complex, or enzyme that then compromises the membrane.

**Predictions**

- Properly prepared amino-terminal GSDMD should not permeabilize protein-free bilayers over cell-relevant exposures.
- Activity should appear when a responsive cellular fraction or purified candidate effector is added.
- Loss of the candidate should prevent lysis downstream of GSDMD cleavage or induced amino-terminal-domain expression.
- Re-expression of the candidate should restore lysis; a catalytically or functionally inactive candidate should not, if the candidate’s activity is required.

#### Mixed mechanism

GSDMD may possess intrinsic membrane activity while another factor determines efficiency, localization, threshold, or repair escape.

**Prediction**

- Direct activity will be demonstrable in minimal membranes, but removal of a cellular factor will alter the concentration threshold, rate, localization, or completeness of cellular lysis rather than eliminating the intrinsic biochemical activity.

---

## 2. Evidence-to-inference-to-experimental conclusion chain

| Supplied evidence | Supported inference | What remains unresolved | Required experiment |
|---|---|---|---|
| GSDMD is genetically necessary for inflammatory-caspase-associated lytic death in the tested cells. | GSDMD is required somewhere in the causal pathway. | Necessity does not identify the immediate physical membrane-disrupting agent. | Biochemical sufficiency in a minimal membrane system. |
| Cleavage separates two domains. | Cleavage is a plausible activation step. | Cleavage could expose a membrane-active surface or an effector-binding surface. | Compare cleavage-matched amino-terminal domain with intact protein under identical membrane conditions. |
| The liberated amino-terminal domain can induce cell death. | The amino-terminal domain contains the relevant downstream activity in cells. | Cells contain many possible secondary effectors; cellular sufficiency is not biochemical directness. | Add the purified domain to protein-free membranes. |
| Intact GSDMD is autoinhibited. | Intact GSDMD is an internal negative control for activation state. | Purified-protein artifacts could override autoinhibition. | Require much lower activity from intact protein and independently verify preparation quality. |
| Cytokine processing and release can be separated. | Cytokine processing or extracellular cytokine alone is not a valid proxy for membrane lysis. | Whether GSDMD directly causes permeability. | Measure membrane permeability and lysis directly; measure cytokine processing and release separately. |

**Current conclusion from the packet:** GSDMD and its liberated amino-terminal domain are causally implicated in lytic death, but the immediate physical mechanism remains undetermined.

---

# 3. Staged study

## Stage 0: define and qualify the molecular reagents

### 0.1 Determine the relevant amino-terminal construct

The packet does not provide the exact cleavage site or fragment boundaries. Before reconstitution:

1. Induce the same inflammatory-caspase-associated condition in the tested cells.
2. Isolate or map the endogenous amino-terminal cleavage product.
3. Define the recombinant construct from the observed termini rather than assuming a boundary.
4. Prepare:
   - cleavage-matched amino-terminal GSDMD;
   - intact GSDMD;
   - the complementary carboxy-terminal domain;
   - matched purification controls;
   - later, selected amino-terminal variants.

**Missing setting requiring validation:** exact amino-acid boundaries.

**Causal purpose:** an incorrectly bounded recombinant fragment could produce a false-negative or artifactual positive membrane result.

### 0.2 Purification and quality control

Purify all proteins through matched procedures and exchange them into the same detergent-free assay buffer. If an affinity tag is used, remove it where possible and compare tagged and untagged material during assay qualification.

For each preparation:

- verify identity and intact mass;
- assess purity and degradation;
- assess soluble concentration after clarification;
- assess monodispersity or aggregation by an orthogonal sizing method;
- retain chromatograms or equivalent quality-control records;
- inventory major co-purifying proteins;
- prepare at least two independent purification batches;
- process a mock purification from a host lacking the GSDMD construct.

A denatured amino-terminal preparation can be included as a supportive control, but it is not sufficient to exclude a denaturable contaminant. Independent purification, mock purification, and activity tracking with the correct protein are more important.

**Missing settings requiring validation**

- expression system;
- purification tag and tag-removal method;
- buffer identity, pH, ionic strength, reducing conditions, and additives;
- temperature and storage duration;
- acceptable aggregation and purity thresholds.

These should be fixed after pilot qualification and then held constant across comparisons.

---

## Stage 1: minimal protein-free membrane reconstitution

### 1.1 Liposome leakage assay

#### Membrane preparation

Prepare large unilamellar liposomes entirely from chemically defined lipids, with no cell extract or membrane proteins. Encapsulate a fluorescent reporter at a concentration that permits quantification of its release, and remove external reporter before the assay.

Use a staged composition strategy:

1. **Minimal bilayer-forming composition:** establishes whether any simple lipid bilayer is susceptible.
2. **Composition panel:** vary major lipid chemical properties rather than relying on one arbitrary membrane.
3. **Tested-cell-informed composition:** if a negative result persists, determine the relevant cellular membrane lipid composition and reproduce its major features in a defined mixture.

The evidence packet contains no information about GSDMD lipid preference or the tested cells’ lipid composition. Therefore, exact lipid identities and molar percentages are **unreported parameters requiring experimental selection and validation**, not facts to be assumed.

Check before protein addition that each vesicle preparation has:

- low and stable spontaneous leakage;
- matched internal and external osmolarity;
- a reproducible maximum-release signal after complete membrane solubilization;
- acceptable size distribution;
- no effect of assay buffer alone.

#### Reaction setup

For each membrane composition, compare:

1. amino-terminal GSDMD;
2. intact GSDMD at matched molar exposure;
3. carboxy-terminal domain;
4. vehicle;
5. matched mock-purification material;
6. denatured amino-terminal GSDMD as a supportive control;
7. a complete-release control used only to define the assay maximum.

Use a log-spaced concentration series rather than one concentration. Define the upper limit by protein solubility, aggregation, and nonspecific activity of the control proteins. Once cellular GSDMD abundance and membrane recruitment are measured, center the informative part of the series around the estimated cellular membrane surface density.

Record fluorescence continuously to resolve kinetics rather than measuring only an endpoint. Normalize release as:

\[
\text{Fractional release}(t)=
\frac{F(t)-F_{\text{initial}}}
{F_{\text{complete release}}-F_{\text{initial}}}.
\]

Also incubate free reporter with each protein to detect direct fluorescence quenching or enhancement.

**Numerical settings not supplied and requiring validation**

- lipid concentration;
- vesicle diameter and extrusion settings;
- reporter identity, size, and concentration;
- protein concentration range and protein-to-lipid ratio;
- reaction volume, temperature, pH, ionic strength, and duration;
- maximum acceptable baseline leakage;
- threshold for calling a response above background.

These should be set from assay qualification, not inferred from the evidence packet.

#### Size-selectivity module

Repeat leakage measurements with at least two encapsulated reporters of different effective sizes in separate vesicle preparations.

**Interpretation**

- Release of a smaller but not larger reporter suggests size-restricted lesions.
- Release of both may indicate larger lesions or generalized disruption.
- Either pattern can support direct membrane action; size selectivity is not required for the direct-action conclusion.

### 1.2 Direct membrane-binding measurement

Measure amino-terminal, intact, and carboxy-terminal GSDMD association with liposomes using a flotation or equivalent separation assay that distinguishes membrane-bound protein from soluble aggregates.

Include:

- protein without liposomes;
- liposomes without protein;
- identical lipid compositions used in the leakage assay;
- recovery controls for all fractions.

Quantify protein in membrane-associated and soluble fractions. Confirm the result with a second binding method if technically feasible.

**Causal interpretation**

- Binding without leakage shows membrane association but not direct disruption.
- Leakage without demonstrable binding requires investigation for transient binding, assay interference, or contamination.
- Correlated binding and leakage strengthen direct action, but leakage is the decisive functional measurement.

### 1.3 Orthogonal planar-bilayer electrophysiology

Form a stable protein-free planar lipid bilayer using one or more compositions that were susceptible in the liposome assay. Verify a low, stable baseline current before protein addition.

Add amino-terminal GSDMD to one side while recording current over time. Compare intact GSDMD, carboxy-terminal domain, vehicle, and mock-purification material under identical conditions. Reverse the side of addition in a separate set to test whether sidedness matters.

Possible signals include:

- discrete current steps;
- sustained increases in conductance;
- irregular transient current events;
- catastrophic loss of bilayer integrity.

The exact pattern distinguishes modes of direct membrane disruption, but any reproducible GSDMD-dependent conductance change in a protein-free bilayer is orthogonal evidence for direct action.

**Missing settings requiring validation:** membrane area, voltage protocol, electrolyte composition, protein dose, filtering, event-detection criteria, and recording duration.

### 1.4 Single-vesicle or giant-vesicle imaging

Expose individual protein-free vesicles to amino-terminal GSDMD while imaging:

- entry of an external fluorescent reporter;
- loss of an encapsulated reporter;
- membrane deformation or rupture;
- GSDMD membrane accumulation, using a labeled preparation whose activity has first been shown to match unlabeled protein.

This distinguishes population-average leakage from a small subset of catastrophically damaged vesicles and links membrane recruitment temporally to permeability.

**Causal interpretation**

Recruitment followed by reporter exchange in individual protein-free vesicles directly connects GSDMD engagement to membrane permeability without another cellular effector.

### Stage 1 decision rule

A strong biochemical case for direct action requires:

1. reproducible permeability of defined protein-free membranes by amino-terminal GSDMD;
2. little or substantially lower activity from intact autoinhibited GSDMD;
3. dose- or surface-density-dependent kinetics;
4. independent confirmation by conductance or single-vesicle imaging;
5. replication across independent protein and membrane preparations;
6. activity at exposures overlapping, or reasonably bracketing, the measured cellular exposure.

A signal seen only at grossly aggregated or experimentally unattainable concentrations is not mechanistically decisive.

---

## Stage 2: generate separation-of-function variants

Minimal reconstitution establishes biochemical sufficiency, but cellular causality requires a perturbation that links that activity to death.

### 2.1 Variant discovery

Because the packet provides no structural or residue-level information, residue identities should not be assumed. Generate a systematic panel of amino-terminal substitutions across candidate surface regions and screen them in the protein-free assays.

Classify variants as:

1. **Binding-defective:** reduced liposome association and reduced leakage.
2. **Binding-competent but permeabilization-defective:** normal or near-normal membrane association but reduced leakage and conductance.
3. **Wild-type-like:** preserves both activities.
4. **Globally defective:** altered folding, solubility, or aggregation; exclude these from causal interpretation.

The second class is especially valuable because it separates membrane recruitment from membrane disruption.

### 2.2 Variant qualification

For each candidate used in cells, require:

- comparable purity and soluble recovery;
- comparable folding and oligomeric quality by the selected quality-control methods;
- intact mass;
- matched concentration;
- reconstitution across multiple doses;
- independent purification replication.

When introduced into full-length GSDMD, additionally verify:

- comparable expression;
- intact autoinhibition before stimulation;
- comparable inflammatory-caspase-associated cleavage;
- production of the expected amino-terminal fragment.

A binding-defective variant can also be tested with a heterologous membrane-targeting module. Restoration of activity by forced targeting would support a recruitment defect. Controls must include the targeting module alone and a targeted permeabilization-defective variant. This experiment is supportive, not independently decisive, because artificial targeting could recruit other factors.

---

## Stage 3: cellular validation in the tested system

### 3.1 Isogenic complementation

Use the same tested cellular background in which GSDMD was genetically necessary. Create or use an isogenic GSDMD-deficient derivative and complement it with:

- full-length wild-type GSDMD;
- two or more independently derived direct-action-defective variants, if available;
- a wild-type-like variant control;
- empty vector.

Expression should be matched as closely as possible to endogenous GSDMD. If stable expression of the active fragment is toxic, use acute inducible expression.

Run two related cellular tests:

1. **Upstream-pathway test:** stimulate the same inflammatory-caspase-associated pathway and compare full-length constructs.
2. **Cleavage-bypass test:** induce the cleavage-matched amino-terminal fragments directly, eliminating differences in upstream activation or cleavage.

**Unreported parameters requiring validation**

- exact cell type and culture conditions;
- inflammatory-caspase trigger;
- timing and dose of stimulation;
- construct-delivery method;
- promoter and expression level;
- number and timing of measurements;
- sample size and statistical model.

### 3.2 Direct lysis measurements

Measure membrane integrity and lysis using at least two orthogonal readouts:

- time-resolved entry of a normally membrane-impermeant reporter;
- release of a constitutive intracellular marker into the medium or an equivalent direct lysis assay;
- cell survival or loss of metabolic competence as a secondary endpoint.

Time-resolved measurements are needed to distinguish initial permeability from terminal lysis.

### 3.3 Activation, localization, and cytokine controls

In the same experiments measure:

- GSDMD expression;
- cleavage and abundance of the amino-terminal fragment;
- membrane recruitment by imaging or biochemical fractionation;
- intracellular processed cytokine;
- extracellular cytokine release.

The exact cytokine identity is not provided and must be matched to the tested system.

Because cytokine processing and release can be experimentally separated, neither should be used as the sole lysis readout. A variant could preserve upstream cytokine processing while failing to cause membrane permeabilization, or alter release without altering processing.

### 3.4 Quantify cell-relevant membrane exposure

Estimate the amount of amino-terminal GSDMD reaching the cellular membrane by calibrated imaging or quantitative fractionation. Use that estimate to compare cellular membrane exposure with the protein-to-lipid or surface-density range active in reconstitution.

**Causal interpretation**

- If wild type restores lysis and a folded, normally cleaved, membrane-localized but reconstitution-defective variant does not, the direct biochemical activity is likely necessary for cellular lysis.
- If a binding-defective variant fails in cells but forced membrane targeting restores both reconstituted and cellular activity, membrane recruitment is likely causal.
- If variants defective in reconstitution retain full cellular lysis, either the reconstitution omitted an essential membrane feature or cells use another effector.

---

## Stage 4: branch for identifying another cellular effector

This stage becomes primary if minimal reconstitution remains negative after protein activity and membrane composition have been adequately challenged, or if cellular lysis dissociates from direct membrane activity.

### 4.1 Cellular-fraction add-back

Prepare soluble and washed membrane fractions from responsive cells. Preferably use GSDMD-deficient cells as the fraction source to prevent endogenous GSDMD from confounding the assay.

Test defined combinations:

1. liposomes plus amino-terminal GSDMD;
2. liposomes plus each cellular fraction;
3. liposomes plus amino-terminal GSDMD plus soluble fraction;
4. liposomes plus amino-terminal GSDMD plus washed membrane fraction;
5. fractions plus intact GSDMD;
6. mock-purification material plus fractions.

A restoring fraction must not permeabilize liposomes on its own under the same conditions.

If activity is restored, classify the requirement using controlled treatments such as protein depletion, protease treatment followed by protease removal, heat treatment, nucleotide depletion, or fractionation by size or charge. Each treatment needs a recovery control because loss of activity could reflect nonspecific damage to the fraction.

### 4.2 Candidate purification and minimal co-reconstitution

Fractionate the restoring material while tracking GSDMD-dependent liposome leakage. Identify candidate components only from fractions whose activity co-purifies.

Then test purified components in a four-condition design:

- GSDMD alone;
- candidate alone;
- GSDMD plus candidate;
- inactive or functionally defective candidate plus GSDMD.

If the candidate is a membrane protein, incorporate it into otherwise defined proteoliposomes. If it is an enzyme, measure its immediate biochemical product in parallel with membrane permeability.

### 4.3 Genetic epistasis

Remove or suppress the candidate in the tested cells and assess:

- upstream inflammatory-caspase activation;
- GSDMD cleavage;
- induced amino-terminal GSDMD abundance;
- membrane localization;
- direct lysis;
- cytokine processing and release separately.

Rescue with wild-type candidate and, where relevant, an inactive candidate.

**Strong support for an indirect effector mechanism would require all three:**

1. GSDMD alone is inactive in adequately validated protein-free membranes;
2. purified candidate restores GSDMD-dependent membrane permeability in defined reconstitution;
3. candidate loss blocks cellular lysis downstream of GSDMD cleavage or amino-terminal-fragment expression, and wild-type candidate rescues it.

---

# 4. Explicit alternative outcomes and conclusions

## Outcome A: strong support for direct membrane action

**Proposed observations**

- Amino-terminal GSDMD binds and permeabilizes protein-free liposomes.
- Intact GSDMD is substantially less active.
- Conductance or single-vesicle permeability confirms the effect.
- Activity occurs at membrane exposure overlapping the cellular estimate.
- Reconstitution-defective variants are folded, cleaved, and membrane-localized but fail to restore cellular lysis.

**Conclusion**

Amino-terminal GSDMD is biochemically sufficient to compromise membranes, and that activity is causally required for cellular lysis. Other factors may regulate efficiency but are not required as the immediate membrane-disrupting effector.

## Outcome B: strong support for another cellular effector

**Proposed observations**

- Qualified amino-terminal GSDMD does not permeabilize a justified panel of protein-free membranes.
- A cellular fraction restores GSDMD-dependent activity.
- A purified candidate plus GSDMD recreates permeability, whereas either alone does not.
- Candidate loss blocks lysis induced by the liberated amino-terminal domain, without preventing GSDMD cleavage or fragment production.
- Wild-type but not inactive candidate rescues.

**Conclusion**

GSDMD acts upstream of another cellular effector that is immediately responsible for membrane compromise.

## Outcome C: combined direct and effector-assisted mechanism

**Proposed observations**

- Amino-terminal GSDMD directly permeabilizes protein-free membranes.
- A cellular factor lowers the required concentration, accelerates kinetics, controls localization, or permits complete lysis.
- Candidate loss shifts or delays lysis rather than abolishing intrinsic activity.

**Conclusion**

GSDMD has direct membrane activity, but a cellular cofactor or regulator is important for efficient lysis. The factor should not be described as the sole membrane-disrupting effector.

## Outcome D: positive reconstitution only at extreme exposure

**Conclusion**

Direct membrane disruption is possible in principle, but its cellular relevance remains uncertain. Quantitative cellular membrane exposure and aggregation controls become decisive.

## Outcome E: negative reconstitution with uncertain reagent activity

Examples include aggregation, incorrect fragment boundaries, inappropriate lipid composition, or absence of a required cellular modification.

**Conclusion**

Mechanism unresolved. A negative assay is not evidence for an indirect effector until these failures are addressed.

## Outcome F: full-length GSDMD is as active as the amino-terminal fragment

**Conclusion**

The assay or protein preparation is inconsistent with the supplied autoinhibition evidence. Investigate degradation, inadvertent cleavage, aggregation, tags, or nonphysiologic membrane conditions before interpreting the result.

## Outcome G: a variant loses both reconstitution activity and folding or cleavage

**Conclusion**

The variant is not mechanistically interpretable. Its cellular phenotype cannot be assigned specifically to loss of membrane action.

## Outcome H: reconstitution-defective variants retain cellular lysis

**Conclusion**

Possible explanations include an incomplete synthetic membrane, a mutation that is defective only in the selected lipid composition, or an indirect cellular effector mechanism. This result triggers broader membrane testing and the fraction-add-back branch.

---

# 5. Reproducibility and analysis plan

- Use independent protein purification batches, independent membrane preparations, and independent cell experiments; technical wells alone are not independent replicates.
- Randomize sample order and blind analysis where feasible.
- Predefine exclusions for vesicle instability, bilayer failure, protein precipitation, and expression mismatch.
- Analyze full dose-response and time-course data, not selected endpoints.
- Report effect sizes and uncertainty intervals.
- Determine replicate number and formal decision thresholds from pilot variance; the packet provides no basis for inventing numerical sample sizes.
- Require concordance among leakage, membrane binding, conductance or imaging, and cellular rescue before making a strong causal claim.

---

# 6. Main assumptions and limits

1. **Recombinant equivalence:** the cleavage-matched recombinant fragment must reproduce the cellular species. Exact boundaries or required modifications are not supplied.
2. **Membrane adequacy:** a negative result in one synthetic composition cannot exclude direct action against a different cellular lipid environment.
3. **Purity:** a positive result could arise from a co-purifying lytic contaminant unless it follows GSDMD through independent preparations and separation-of-function variants.
4. **Mutant specificity:** loss-of-function substitutions may alter folding, cleavage, or an effector-binding surface; these properties must be measured.
5. **Cellular repair:** initial permeability and terminal lysis may differ because cells can potentially respond to membrane injury. Both must be measured.
6. **Non-exclusivity:** direct reconstitution establishes sufficiency, not that no cellular cofactor modulates the process.
7. **Cytokine interpretation:** cytokine processing, cytokine release, and lysis are distinct readouts and must remain analytically separate.

## Final causal standard

The most decisive support for direct membrane action would be the combination of **protein-free membrane permeabilization by cleavage-matched amino-terminal GSDMD**, **orthogonal conductance or single-vesicle confirmation**, and **loss of cellular lysis in membrane-action-defective variants despite normal expression, cleavage, folding, and membrane localization**. Conversely, a compelling indirect mechanism requires **minimal co-reconstitution with a second purified effector plus downstream cellular epistasis**, not merely failure of one liposome assay.
